Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule linéaire :
[-(CH2)3CONHOH]2
Numéro CAS:
Poids moléculaire :
204.22
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
95%
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
assay
95%
mp
153-155 °C (lit.)
functional group
amine
SMILES string
ONC(=O)CCCCCCC(=O)NO
InChI
1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)
InChI key
IDQPVOFTURLJPT-UHFFFAOYSA-N
Biochem/physiol Actions
HDAC inhibitor
Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. SBHA inhibits the activity of HDAC1 and HDAC3 with IC50 values of 250 and 300 nM, respectively. SBHA inhibits proliferation, and induces apoptosis in several cancer cell lines. SBHA has been shown to activate Notch signaling in medullary thyroid carcinoma (MTC) cells.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Li Ning et al.
The oncologist, 13(2), 98-104 (2008-02-29)
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) malignancy that frequently metastasizes and has limited treatments. We recently reported that ectopic expression of Notch-1 in human MTC cells suppresses growth. The objective of this study was to evaluate the ability
Jiansen Li et al.
Oncology reports, 37(1), 458-464 (2016-12-23)
Anaplastic thyroid cancer (ATC), usually derived from well-differentiated thyroid cancers is one of the most lethal human endocrine malignancies. In the present study, we report that in human ATC tumor tissue samples exist undetectable Notch1 and the active Notch1 intracellular
Mohamed Rahmani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4849-4860 (2014-07-30)
The aim of this study is to explore the efficacy and define mechanisms of action of coadministration of the PI3K/mTOR inhibitor BEZ235 and pan-HDAC inhibitor panobinostat in diffuse large B-cell lymphoma (DLBCL) cells. Various DLBCL cells were exposed to panobinostat